OncoMatch

OncoMatch/Clinical Trials/NCT05989724

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Is NCT05989724 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SON-DP for solid tumor.

Phase 1RecruitingQurgen Inc.NCT05989724Data as of May 2026

Treatment: SON-DPThis proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Breast Carcinoma

Pancreatic Cancer

Ovarian Cancer

Colorectal Cancer

Disease stage

Metastatic disease required

relapsed/refractory intolerant to standard of care therapies for advanced/metastatic solid tumors

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: standard of care therapies — advanced/metastatic

relapsed/refractory intolerant to standard of care therapies for advanced/metastatic solid tumors

Cannot have received: investigational therapy

Participation in investigational study within 2 weeks or 5 half-lives, whichever is shorter of the first dose of study treatment.

Cannot have received: anticancer therapy

Anticancer therapy within 5 half-lives or 2 weeks (whichever is shorter) prior to study entry.

Lab requirements

Blood counts

adequate hematological function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Banner MD Anderson Cancer Center (BMDACC) · Gilbert, Arizona
  • Henry Ford Health System · Detroit, Michigan
  • Carolina BioOncology Institute · Huntersville, North Carolina
  • Stephenson Cancer Center, University of Oklahoma · Oklahoma City, Oklahoma
  • MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify